[CAS NO. 1001600-54-9] MV1
PRODUCTS SPECIFICATIONS [1001600-54-9]
DESCRIPTION [1001600-54-9]
Overview
| MDL | MFCD32062761 |
|---|---|
| Molecular Weight | 576.73 |
| Molecular Formula | C33H44N4O5 |
| SMILES | O=C(OC)[C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC([C@H]3N(C([C@H](C4CCCCC4)NC([C@H](C)NC)=O)=O)CCC3)=O |
Summary
In Vitro
MV1 (0.08-20 μM; 24 h) inhibits the growth of EVSAT cells
[1]
.
MV1 (5 μM; 0-60 min) treatment causes rapid loss of c-IAP1 and c-IAP2 in MDA-MB-231 cells
[1]
.
MV1 (5 μM; 1 h) treatment inducing degradation of c-IAP1 and c-IAP2 is dependent on proteasomal machinery but not on caspase activation
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | EVSAT cells |
| Concentration: | 0.08-20 μM |
| Incubation Time: | 24 hours |
| Result: | Showed IC 50 value of 5 μM for EVSAT cells. |
Western Blot Analysis [1]
| Cell Line: | MDA-MB-231 cells |
| Concentration: | 5 μM |
| Incubation Time: | 0-60 min |
| Result: | Showed the decreasement of c-IAP1 and 2 protein levels by as early as two minutes following exposure. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 125 mg/mL ( 216.74 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7339 mL | 8.6696 mL | 17.3391 mL |
| 5 mM | 0.3468 mL | 1.7339 mL | 3.4678 mL |
| 10 mM | 0.1734 mL | 0.8670 mL | 1.7339 mL |
References
- [1] Tomoshige S, et al. Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligand. Bioorg Med Chem. 2016 Jul 15;24(14):3144-8.
- [2] Eugene Varfolomeev, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81.